Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Price Target Raised to $4.00

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) had its price target boosted by B. Riley Financial from $3.00 to $4.00 in a research report sent to investors on Wednesday,Benzinga reports. They currently have a buy rating on the stock.

Other equities analysts also recently issued reports about the stock. D. Boral Capital increased their price objective on shares of Lineage Cell Therapeutics from $2.00 to $3.00 and gave the company a “buy” rating in a research note on Friday, March 6th. HC Wainwright restated a “buy” rating and set a $9.00 target price on shares of Lineage Cell Therapeutics in a report on Tuesday. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $5.33.

Lineage Cell Therapeutics Price Performance

NYSEAMERICAN LCTX opened at $1.49 on Wednesday. The stock has a market capitalization of $371.14 million, a PE ratio of -5.32 and a beta of 1.74. The business has a 50 day simple moving average of $1.69 and a two-hundred day simple moving average of $1.69. Lineage Cell Therapeutics has a 1-year low of $0.37 and a 1-year high of $2.09.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last released its quarterly earnings results on Thursday, March 5th. The company reported $0.00 earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.07. Lineage Cell Therapeutics had a negative return on equity of 76.13% and a negative net margin of 436.47%.The company had revenue of $6.61 million for the quarter, compared to analyst estimates of $1.96 million. On average, analysts anticipate that Lineage Cell Therapeutics will post -0.12 EPS for the current fiscal year.

Institutional Investors Weigh In On Lineage Cell Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of LCTX. SG Americas Securities LLC acquired a new stake in Lineage Cell Therapeutics in the fourth quarter valued at approximately $25,000. Citizens Financial Group Inc. RI purchased a new stake in shares of Lineage Cell Therapeutics during the 3rd quarter valued at $25,000. Jump Financial LLC purchased a new stake in shares of Lineage Cell Therapeutics during the 2nd quarter valued at $28,000. DLD Asset Management LP acquired a new stake in shares of Lineage Cell Therapeutics in the 4th quarter worth $33,000. Finally, Define Financial LLC purchased a new position in Lineage Cell Therapeutics during the 4th quarter worth $33,000. Hedge funds and other institutional investors own 62.47% of the company’s stock.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.

Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.